Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Probiodrug Ag

Anke Piechotta

Stephan Schilling

Jens-Ulrich Rahfeld

Stephen D Gillies

Holger Cynis

Martin Kleinschmidt

Hans-Ulrich Demuth

Mirko Buchholz

Daniel Ramsbeck

Kathrin Gnoth

Diane Meitzner

Stefanie Geissler

Miriam Linnert

Linda Liebe

Christian Jäger

The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases

The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid &#x3b2; (A&#x3b2;) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 A&#x3b2; can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of A&#x3b2;-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 A&#x3b2; in an isolated sample.

Anti-isoAsp7 amyloid &#x3b2; (A&#x3b2;) antibodies and uses thereof

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A&#x3b2; N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A&#x3b3; N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Humanized antibodies

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A&#x3b2; N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A&#x3b2; N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Growing community of inventors

Halle, Germany

Anke Piechotta